{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:19:02Z","timestamp":1790533142606,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jpba.2022.115191","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T03:00:52Z","timestamp":1669690852000},"page":"115191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS\/MS method"],"prefix":"10.1016","volume":"224","author":[{"given":"Zhe","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-ke","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ping","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-chang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10138","key":"10.1016\/j.jpba.2022.115191_bib1","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/S0140-6736(18)31320-5","article-title":"Type 1 diabetes","volume":"391","author":"DiMeglio","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jpba.2022.115191_bib2","first-page":"228","article-title":"The worldwide epidemiology of type 2 diabetes mellitus--present and future perspectives, Nature reviews","volume":"8","author":"Chen","year":"2011","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.jpba.2022.115191_bib3","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1002\/cpt.1496","article-title":"Modulation of CYP450 activities in patients with type 2 diabetes","volume":"106","author":"Gravel","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.jpba.2022.115191_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/BF03261933","article-title":"Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes","volume":"51","author":"Dostalek","year":"2012","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.jpba.2022.115191_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/00498254.2019.1648911","article-title":"Cytochrome P450: genotype to phenotype","volume":"50","author":"Waring","year":"2020","journal-title":"Xenobiotica"},{"key":"10.1016\/j.jpba.2022.115191_bib6","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.2147\/DDDT.S149069","article-title":"The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo","volume":"12","author":"Sychev","year":"2018","journal-title":"Drug Des., Dev. Ther."},{"issue":"7","key":"10.1016\/j.jpba.2022.115191_bib7","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/jcph.1093","article-title":"Disease-drug interactions in inflammatory states via effects on CYP-mediated drug clearance","volume":"58","author":"Coutant","year":"2018","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"10.1016\/j.jpba.2022.115191_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21051835","article-title":"The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation","volume":"21","author":"Poznyak","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jpba.2022.115191_bib9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jpba.2018.10.012","article-title":"A UHPLC-MS\/MS method coupled with liquid-liquid extraction for the quantitation of phenacetin, omeprazole, metoprolol, midazolam and their metabolites in rat plasma and its application to the study of four CYP450 activities","volume":"163","author":"Wang","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115191_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/3619723","article-title":"Influences of anlotinib on cytochrome P450 enzymes in rats using a cocktail method","volume":"2017","author":"Sun","year":"2017","journal-title":"BioMed. Res. Int."},{"issue":"1","key":"10.1016\/j.jpba.2022.115191_bib11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jep.2013.11.016","article-title":"Effects of aescin on cytochrome P450 enzymes in rats","volume":"151","author":"Huang","year":"2014","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.jpba.2022.115191_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-020922","article-title":"Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study","volume":"8","author":"Gravel","year":"2018","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.jpba.2022.115191_bib13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/js980255z","article-title":"Human cytochromes P450 mediating phenacetin O-deethylation in vitro: validation of the high affinity component as an index of CYP1A2 activity","volume":"87","author":"Venkatakrishnan","year":"1998","journal-title":"J. Pharm. Sci."},{"issue":"4","key":"10.1016\/j.jpba.2022.115191_bib14","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/dmd.114.061200","article-title":"In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population","volume":"43","author":"Hu","year":"2015","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"issue":"6","key":"10.1016\/j.jpba.2022.115191_bib15","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/bcp.14247","article-title":"CYP2D6 polymorphism and its impact on the clinical response to metoprolol: a systematic review and meta-analysis","volume":"86","author":"Meloche","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jpba.2022.115191_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1124\/dmd.120.000261","article-title":"Functional characterization of 40 CYP3A4 variants by assessing midazolam 1\u2032-hydroxylation and testosterone 6\u03b2-hydroxylation","volume":"49","author":"Kumondai","year":"2021","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"key":"10.1016\/j.jpba.2022.115191_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12986-016-0126-6","article-title":"Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake","volume":"13","author":"Urry","year":"2016","journal-title":"Nutr. Metab."},{"issue":"2","key":"10.1016\/j.jpba.2022.115191_bib18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00008571-199204000-00004","article-title":"of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1","volume":"2","author":"Gu","year":"1992","journal-title":"Pharmacogenetics"},{"issue":"2","key":"10.1016\/j.jpba.2022.115191_bib19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0269881116668595","article-title":"A case-control field study on the relationships among type 2 diabetes, sleepiness and habitual caffeine intake","volume":"31","author":"Urry","year":"2017","journal-title":"J. Psychopharmacol. (Oxf., Engl. )"},{"issue":"3","key":"10.1016\/j.jpba.2022.115191_bib20","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.toxlet.2007.03.010","article-title":"Toxicity of diazinon and its metabolites increases in diabetic rats","volume":"170","author":"Ueyama","year":"2007","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.jpba.2022.115191_bib21","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.cbi.2016.04.040","article-title":"In vitro metabolism of phenytoin in 36 CYP2C9 variants found in the Chinese population","volume":"253","author":"Chen","year":"2016","journal-title":"Chem. -Biol. Interact."},{"key":"10.1016\/j.jpba.2022.115191_bib22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.2337\/diab.12.5.414","article-title":"Disappearance rate of tolbutamide in normal subjects and in diabetes mellitus, liver cirrhosis, and renal disease","volume":"12","author":"Ueda","year":"1963","journal-title":"Diabetes"},{"key":"10.1016\/j.jpba.2022.115191_bib23","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2147\/DDDT.S106175","article-title":"Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro","volume":"10","author":"Wang","year":"2016","journal-title":"Drug Des., Dev. Ther."},{"issue":"1","key":"10.1016\/j.jpba.2022.115191_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","article-title":"CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment","volume":"97","author":"Jin","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"issue":"5","key":"10.1016\/j.jpba.2022.115191_bib25","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/clpt.2010.137","article-title":"Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan","volume":"88","author":"Abduljalil","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.jpba.2022.115191_bib26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/clpt.2013.193","article-title":"An investigation of CYP2D6 genotype and response to metoprolol CR\/XL during dose titration in patients with heart failure: a MERIT-HF substudy","volume":"95","author":"Batty","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.jpba.2022.115191_bib27","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2215-0366(19)30138-5","article-title":"CYP2D6 testing to guide risperidone and aripiprazole therapy","volume":"6","author":"Bousman","year":"2019","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"10.1016\/j.jpba.2022.115191_bib28","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/pds.4200","article-title":"The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly","volume":"26","author":"Bahar","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jpba.2022.115191_bib29","series-title":"Medical Genetics Summaries","article-title":"Propafenone Therapy and CYP2D6 Genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.jpba.2022.115191_bib30","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1016\/j.ejps.2017.05.033","article-title":"Population pharmacokinetics of carvedilol enantiomers and their metabolites in healthy subjects and type-2 diabetes patients","author":"Nardotto","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.jpba.2022.115191_bib31","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3109\/00498254.2016.1141437","article-title":"Decreased exposure of atorvastatin in diabetic rats partly due to induction of hepatic Cyp3a and Oatp2","volume":"46","author":"Shu","year":"2016","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.jpba.2022.115191_bib32","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1124\/dmd.118.085902","article-title":"Prediction of atorvastatin pharmacokinetics in high-fat diet and low-dose streptozotocin-induced diabetic rats using a semiphysiologically based pharmacokinetic model involving both enzymes and transporters","volume":"47","author":"Wang","year":"2019","journal-title":"Drug Metab. Dispos.: Biol. fate Chem."},{"issue":"1","key":"10.1016\/j.jpba.2022.115191_bib33","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/s41467-020-15978-3","article-title":"MD2 activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522006124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:24:41Z","timestamp":1760001881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522006124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":33,"alternative-id":["S0731708522006124"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115191","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of CYP450 activities in diabetes mellitus rats by a UHPLC-MS\/MS method","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115191"}}